Hyperlipidemia Models and Efficacy Services
Due to improvements in standard of living and the evolution of average dietary structures, the occurrence of hyperlipidemia (HLP) is increasing. HLP poses a grave threat to human health because it can lead to the development of metabolic disorders in the body, which in turn cause cardiovascular diseases such as atherosclerosis, coronary heart disease, and myocardial infarction. The prevention of hyperlipidemia and the development of related therapeutic medications are of incredible significance.
- Hyperlipidemia Models
-
-B6-hPCSK9 mouse model: A humanized model generated by replacing the PCSK9 coding region of C57BL/6JGpt mice with the human counterpart. These mice can develop hyperlipidemia after feeding a high-cholesterol diet and are useful for evaluating PCSK9-targeting antibody drugs.
-B6-hPCSK9-UTR mouse model: The coding region of the PCSK9 gene and the 3' UTR region of C57BL/6JGpt mice are humanized by full fragment substitution to construct the B6-hPCSK9-UTR mouse model, which can develop hyperlipidemia after feeding a high-cholesterol diet and is suitable for the evaluation of siRNA drugs targeting PCSK9.
- Test Items
-
- Body weight, blood lipids (cholesterol-related indicators), pathological tests (immunohistochemistry, special staining, etc.),
- Gene expression assays (q-PCR, WB), etc.